97270 ⎘
Immunoglobulins specific features characterized by post-translational modification Glycosylation, sialylation, or fucosylation
VHH for application in tissue repair, organ regeneration, organ replacement and tissue engineering
#1202Immunoglobulin constant region Fc receptor binding agents
#1203Antibody composition-producing cell
#1204ANTIBODIES THAT BIND NOVEL PCSK9 VARIANTS
#1205Combination therapy of an anti-CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor
#1206COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES
#1207Anti-OX40 antibodies
#1208Immunoglobulin against the anthrax toxin
#1209Optimized Fc variants and methods for their generation
#1210Method for optimizing post-translational modifications on recombinant proteins
#1211OPTIMIZED FC VARIANTS
#1212Human C-FMS antigen binding proteins
#1213Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies
#1214Decreasing ornithine production to decrease high mannose glycoform content of recombinant proteins
#1215Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
#1216Humanized or chimeric CD3 antibodies
#1217AGLYCOSYLATED ANTI-Bb ANTIBODIES AND USES THEREOF
#1218AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
#1219Methods of treatment with bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1
#1220Multispecific domain exchanged common variable light chain antibodies
#1221Anti-PDL1 antibody formulations
#1222Glycoengineered binding protein compositions
#1223Optimized Fc variants and methods for their generation
#1224Antibody formulations and methods for treating AL amyloidosis
#1225Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
#1226Methods for modulating mannose content of recombinant proteins
#1227Optimized Fc variants
#1228Pharmaceutical composition for treatment and/or prevention of cancer
#1229Engineered immunoglobulin Fc polypeptides displaying improved complement activation
#1230Bispecific antigen-binding constructs targeting HER2
#1231Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
#1232Modified glycoprotein, protein-conjugate and process for the preparation thereof
#1233Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
#1234Anti-LAMP1 antibodies and antibody drug conjugates, and uses thereof
#1235METHODS FOR CONTROLLING PROTEIN GLYCOSYLATION
#1236Hyper-glycosylated antibodies with selective Fc receptor binding
#1237Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
#1238Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibody
#1239Antibody drug conjugates (ADC) that bind to FLT3 proteins
#1240ANTI-KIR ANTIBODIES
#1241Production of recombinant proteins with simple glycoforms
#1242CD27 single chain molecules and encoding nucleic acids
#1243METHODS OF REDUCING SERUM LEVELS OF FC-CONTAINING AGENTS USING FCRN ANTAGONISTS
#1244ANTI-TENASCIN-C A2 ANTIBODIES AND METHODS OF USE
#1245Immunoconjugates
#1246Coagulation Factor-Targeting to TLT-1 on Activated Platelets
#1247GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION
#1248SIALYLATED GLYCOPROTEINS
#1249Methods of treating cancers using PD-1 axis binding antagonists and taxanes
#1250Connective Tissue Growth Factor Antibodies
#1251Anti-C5 antibodies having improved pharmacokinetics
#1252Human PAC1 antibodies
#1253Modified glycoprotein, protein-conjugate and process for the preparation thereof
#1254Manufacturing methods to control C-terminal lysine, galactose and sialic acid content in recombinant proteins
#1255GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION
#1256ANTI-CEA ANTIBODIES
#1257MONOVALENT ANTIBODY FRAGMENTS USEFUL AS THERAPEUTICS
#1258Human monoclonal antibodies specific for glypican-3 and use thereof
#1259Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
#1260MONOCLONAL ANTIBODIES TO TRANSFERRIN AND TRANSFERRIN RECEPTOR ANTIGENS, AND USES THEREOF
#1261Methods for controlling the galactosylation profile of recombinantly-expressed proteins
#1262Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
#1263Cells producing Fc-containing molecules having altered glycosylation patterns and methods and use thereof
#1264Methods Of Identifying Anti-Inflammatory Compounds
#1265Disease characterization from fused pathology and radiology data
#1266Antibodies against IL-1 beta
#1267ANTIGEN BINDING PROTEINS
#1268Method for the production of a glycosylated immunoglobulin
#1269METHODS FOR MODULATING THE GLYCOSYLATION PROFILE OF RECOMBINANT PROTEINS USING SUGARS
#1270USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF INFLAMMATION AND BACTERIAL INFECTIONS
#1271OLIGOSACCHARIDE COMPOSITIONS, GLYCOPROTEINS AND METHODS TO PRODUCE THE SAME IN PROKARYOTES
#1272THROMBOPOIETIN RECEPTOR LIGANDS FOR NEUROPROTECTION
#1273Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
#1274Human monoclonal antibodies to O8E
#1275Humanized or chimeric CD3 antibodies
#1276Antagonists to IL-6 to raise albumin and/or lower CRP
#1277Anti-interleukin-33 antibodies and uses thereof
#1278HUMANIZED, ANTI-N2 ANTIBODIES AND METHODS OF TREATING ISCHEMIA-REPERFUSION INJURY
#1279Glycosylated PACAP/VIP analogues with enhanced CNS penetration for treatment of neurodegenerative diseases
#1280Cancer stem cell-specific molecule
#1281LOW MANNOSE ADALIMUMAB COMPOSITIONS AND USES THEREOF
#1282Conjugate of biologically active polypeptide monomer and immunoglobulin Fc fragment with reduced receptor-mediated clearance, and the method for preparing the same
#1283Methods for producing sialylated therapeutic proteins
#1284Methods for controlling the galactosylation profile of recombinantly-expressed proteins
#1285Methods of treatment by administering an anti-BAFFR antibody therapeutic formulation
#1286Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
#1287Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof
#1288Methods for controlling fucosylation levels in proteins
#1289METHODS TO CONTROL PROTEIN HETEROGENEITY
#1290Transglycosylation activity of glycosynthase mutants of an endo-beta-N-acetylglucosaminidase (endo-D) from
#1291Glycoengineered antibody drug conjugates
#1292HER2-specific monoclonal antibodies and conjugates thereof
#1293Anti-nodal antibodies and methods of using same
#1294Method of co-expressing a glycoprotein and a single-subunit olicosaccharyltransferase in a plant
#1295Antagonists of IL-6 to prevent or treat thrombosis
#1296SIALYLATED GLYCOPROTEINS
#1297Quantitative control of sialylation and specific mono-sialylation
#1298Heteromultimers with reduced or silenced effector function
#1299ANTIBODIES DIRECTED AGAINST AMYLOID-BETA PEPTIDE AND METHODS USING SAME
#1300ANTI-CRTH2 ANTIBODIES AND METHODS OF USE
#1301Fucosylation-deficient cells
#1302Methods for the treatment of neurodegeneration
#1303METHOD FOR PREPARING ANTIBODIES HAVING IMPROVED PROPERTIES
#1304Bispecific HER2 and HER3 antigen binding constructs
#1305ANTIGEN BINDING MOLECULES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION
#1306ANTIGEN BINDING MOLECULES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION
#1307Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
#1308MOLECULAR LABELING METHODS
#1309Methods of cell culture
#1310FC-RECEPTOR BINDING MODIFIED ASYMMETRIC ANTIBODIES AND METHODS OF USE
#1311ANTI-CANCER TREATMENTS WITH ANTI-EGFR ANTIBODIES HAVING A LOW FUCOSYLATION
#1312N-acetylhexosamine-containing N-glycans in glycoprotein products
#1313Anti-FAP antibodies and methods of use
#1314Anti-FAP antibodies and methods of use
#1315Site-specific glycoengineering of targeting moieties
#1316Anti-FOLR1 antibody
#1317Efficient selectivity of recombinant proteins
#1318Anti-KIR3D antibodies
#1319Monospecific polypeptide reagents
#1320Antigen-Binding Molecule for Promoting Disappearance of Antigen via Fc gamma RIIB
#1321Methods for producing fabs and bi-specific antibodies
#1322Human PAC1 antibodies
#1323METHODS FOR MODULATING THE GLYCOSYLATION PROFILE OF RECOMBINANT PROTEINS USING DISSOLVED OXYGEN
#1324Methods for increasing mannose content of recombinant proteins
#1325Use of IGG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and incidents via the mucosa
#1326Method for preparing glycan-hydrolyzed antibody, and homogeneous glycosylated antibody
#1327CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIES
#1328Solid phase TGase-mediated conjugation of antibodies
#1329Fucosidase from bacteroides and methods using the same
#1330Methods and compositions with immune therapy for treatment of dementia
#1331Production methods
#1332Anti-FGFR2 antibodies and pharmaceutical compositions thereof
#1333Therapeutic use of anti-CS1 antibodies
#1334Low concentration antibody formulations
#1335Anti-inflammatory polypeptides
#1336Anti-CD83 antibodies and use thereof
#1337Methods for increasing -glycan occupancy and reducing production of hybrid -glycans in strains lacking Alg3 expression
#1338Carbohydrate phosphonate derivatives as modulators of glycosylation
#1339Use of human cells of myeloid leukemia origin for expression of antibodies
#1340HIGHLY GALACTOSYLATED ANTI-HER2 ANTIBODIES AND USES THEREOF
#1341Human monoclonal antibodies specific for glypican-3 and use thereof
#1342Highly galactosylated anti-TNF-α antibodies and uses thereof
#1343Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with P75
#1344Amyloid-beta binding proteins
#1345METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING SICKLE-CELL DISEASE
#1346METHODS FOR IMPROVING SAFETY OF BLOOD-BRAIN BARRIER TRANSPORT
#1347Anti-HER2 glycoantibodies and uses thereof
#1348ANTI-CD20 GLYCOANTIBODIES AND USES THEREOF
#1349Modified Antigen Binding Molecules With Altered Cell Signaling Activity
#1350Process of modulating man5 and/or afucosylation content of a glycoprotein composition
#1351Anti-TNF-alpha glycoantibodies and uses thereof
#1352Human anti-tau antibodies
#1353Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
#1354Yeast strains producing mammalian-like complex N-glycans
#1355Inert format
#1356Antibodies to IL-6 and use thereof
#1357Antibodies to TNF α and use thereof
#1358Methods of Treating Hematological Proliferative Disorders by Targeting EphA3 Expressed on Aberrant Vasculature in Bone Marrow
#1359Ang2 antibodies
#1360Methods of use of anti-CD19 antibodies with reduced immunogenicity
#1361Therapeutic use of antibodies to HGF
#1362Methods for reducing glycoprotein aggregation
#1363Engineered monomeric antibody fragments
#1364Modified antibody, antibody-conjugate and process for the preparation thereof
#1365OPTIMIZED Fc VARIANTS
#1366Use of ADCC-optimized antibodies for treating low-responder patients
#1367Humanized anti-interleukin 3 receptor alpha chain antibodies
#1368Modified glycoproteins
#1369ANTIGEN PRESENTING CELL TARGETED VACCINES
#1370Anti-VEGF antibodies and their uses
#1371Aglycosylated anti-properdin antibodies
#1372Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
#1373Glyco-engineered antibodies
#1374Compositions and methods for inhibiting pathogen infection
#1375Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
#1376COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE
#1377DAC HYP compositions and methods
#1378Antibodies to IL-6 and use thereof
#1379Method of improving patient survivability and quality of life by administering an anti-IL-6 antibody
#1380Anti-IL-6 antibody for use in the treatment of cachexia
#1381Monoclonal antibodies with enhanced ADCC function
#1382Antibodies to CD70
#1383Methods for producing recombinant glycoproteins with modified glycosylation
#1384Expression vectors containing isolated nucleic acids encoding anti-human IL-6 antibody
#1385Modified antibody, antibody-conjugate and process for the preparation thereof
#1386GLYCOPROTEIN PREPARATIONS
#1387Human anti-tau antibodies
#1388Methods related to denosumab
#1389Fc variants with increased affinity for FcyRIIc
#1390Bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1
#1391FCRN antagonists and methods of use
#1392THERAPEUTIC AND DIAGNOSTIC TARGET
#1393METHODS OF EVALUATING AND MAKING BIOLOGICS
#1394DAC HYP compositions and methods
#1395Anti-Siglec-8 antibodies and methods of use thereof
#1396DAC HYP compositions and methods
#1397Treating anemia in chronic IL-6 associated diseases using anti-IL-6 antibodies
#1398Use of high flux SCFA-derivatized monosaccharides in recombinant glycoprotein production
#1399Glycoprotein
#1400Engineered immunoglobulin FC polypeptides
#1401Methods to control protein heterogeneity
#1402Methods to control protein heterogeneity
#1403Method for in vivo production of deglycosylated recombinant proteins used as substrate for downstream protein glycoremodeling
#1404Dimeric protein with triple mutations
#1405Secretory immunoglobulin complex
#1406Methods of reducing IL-6 activity for disease treatment
#1407NOVEL THERAPEUTIC TREATMENTS WITH ANTI-HER2 ANTIBODIES HAVING A LOW FUCOSYLATION
#1408GLYCAN-MODIFIED ANTI-CD4 ANTIBODIES FOR HIV PREVENTION AND THERAPY
#1409Monoclonal antibodies to human proinflammatory cytokines and methods for treating inflammatory diseases
#1410Humaneered anti-factor B antibody
#1411Antibodies against amyloid beta 4 with glycosylation in the variable region
#1412Methods for controlling the galactosylation profile of recombinantly-expressed proteins
#1413Monoclonal antibodies with enhanced ADCC function
#1414Surface anchored light chain bait antibody display system
#1415Compositions and methods for targeting type 1 interferon producing cells
#1416Human monoclonal antibody
#1417GLYCOENGINEERED BINDING PROTEIN COMPOSITIONS
#1418ENZYMATIC MODIFICATION OF ANTI-AQP4 AUTOANTIBODY FOR MODULATING NEUROMYELITIS OPTICA
#1419Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
#1420Antibodies to IL-6 and use thereof
#1421Anti-FGFR2 antibodies and methods of use thereof for treating cancer
#1422Single chain trail fusion polypeptides and encoding nucleic acids
#1423Antibody composition-producing cell
#1424Antibodies against the CXC-ELR family of chemokines
#1425Anti-transferrin receptor antibodies and methods of use
#1426Single chain CD40L fusion polypeptides
#1427Nucleic acid molecules encoding antibodies which bind CCR4 and uses thereof
#1428Monoclonal Olfml-3 antibodies and uses thereof
#1429Antagonist antibodies and their fab fragments against GPVI and uses thereof
#1430Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
#1431Chimeric Fc-gamma receptor and method for determination of ADCC activity by using the receptor
#1432Hyperglycosylated binding polypeptides
#1433GITR antigen binding proteins and methods of use thereof
#1434Therapeutic canine immunoglobulins and methods of using same
#1435Labeling and detection of post translationally modified proteins
#1436Methods for controlling the galactosylation profile of recombinantly-expressed proteins
#1437High concentration antibody and protein formulations
#1438ABETA ANTIBODY FORMULATION
#1439TREATMENT OF CHRONIC INFLAMMATORY CONDITIONS
#1440Caninized anti-nerve growth factor antibodies
#1441Optimized Fc variants
#1442Non-sialylated anti-inflammatory polypeptides
#1443Optimized Fc variants and methods for their generation
#1444FUSION PROTEINS COMPRISING IGG2 HINGE DOMAINS
#1445Diagnosing and treating IGA nephropathy
#1446Methods for increasing mannose content of recombinant proteins
#1447Human growth hormone receptor antagonist antibodies and methods of use thereof
#1448Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
#1449Production of recombinant proteins with simple glycoforms
#1450Immunoglobulins with reduced aggregation
#1451Anti-human CTGF antibody
#1452Aglycosylated Fc-containing polypeptides with cysteine substitutions
#1453Avian Derived Antibodies
#1454Methods for increasing N-glycan occupancy and reducing production of hybrid N-glycans in pichia pastoris strains lacking ALG3 expression
#1455Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (ALS)
#1456Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
#1457Anti-B7-H4 antibodies and immunoconjugates
#1458Humanized neuraminidase antibody and methods of use thereof
#1459Methods to control protein heterogeneity
#1460Pertuzumab variants and evaluation thereof
#1461Production of heterodimeric proteins
#1462Endoglycosidase from and methods using it
#1463Thrombin-binding antibody molecules
#1464HIGHLY GALACTOSYLATED ANTIBODIES
#1465Methods of preventing and removing trisulfide bonds
#1466Site-specific antibody-drug conjugation through glycoengineering
#1467Anti-CD19 antibodies with reduced immunogenicity
#1468Antibody purification and purity monitoring
#1469Interleukin-2 muteins for the expansion of T-regulatory cells
#1470Methods of cell culture
#1471Methods of cell culture
#1472Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
#1473Separation method for fucosylated antibodies
#1474Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
#1475Antibodies to CD70
#1476Process for antibody G1 glycoform production
#1477Human tissue factor antibody and uses thereof
#1478Method of modulating the activity of functional immune molecules
#1479Amyloid-beta binding proteins
#1480Method of treating pain with anti-human NGF antibody
#1481Combination therapy of anti-HER3 antibodies
#1482Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
#1483Methods for preparation of fucose-linked site specific conjugates of proteins with toxins, adjuvants, detection labels and pharmacokinetic half life extenders
#1484Anti-CEA antibodies
#1485Anti-FOLR1 antibody
#1486Optimized antibodies that target HM1.24
#1487Compositions comprising TNF-specific antibodies for oral delivery and methods of use thereof to treat inflammatory bowel disease
#1488Bispecific anti-EGFR/anti IGF-1R antibodies
#1489Glycosylated antibodies
#1490Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof
#1491Surface, anchored Fc-bait antibody display system
#1492Functionalized polypeptides
#1493Monoclonal antibodies with enhanced ADCC function
#1494Antibodies to CD70
#1495Antibodies to CD70
#1496Human monoclonal antibodies to O8E
#1497Antigen presenting cell targeted anti-viral vaccines
#1498Heterodimer protein composition
#1499Treatment of tumors using specific anti-L1 antibody
#1500Antibodies to EphA3